(Circulation. 2000;102:113.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Endogenous Tissue Factor Pathway Inhibitor Modulates Thrombus Formation in an In Vivo Model of Rabbit Carotid Artery Stenosis and Endothelial Injury
From the Department of Internal Medicine and Cardiovascular Sciences, Division of Cardiology, and Department of Zootechnology (L.R.), University of Naples Federico II, Naples, Italy.
Correspondence to Paolo Golino, MD, PhD, Division of Cardiology, University of Naples Federico II, via Sergio Pansini 5, 80131 Naples, Italy. E-mail golino{at}unina.it
Background—Tissue factor pathway inhibitor (TFPI) is the sole known inhibitor of the extrinsic coagulation pathway of physiological importance; however, its role in modulating thrombosis in vivo is still unclear.
Methods and Results—Intravascular thrombosis was initiated by placing an external constrictor around endothelially injured rabbit carotid arteries (n=10). Carotid blood flow velocity was measured by a Doppler flow probe. After placement of the constrictor, cyclic flow reductions (CFRs), due to recurrent thrombosis, developed at the site of stenosis. Transstenotic TFPI plasma activity was measured in blood samples before induction of CFRs and after 30, 60, and 180 minutes of CFRs. TFPI plasma activity distal to the site of thrombosis was significantly lower than the corresponding proximal values at 30, 60, and 180 minutes of CFRs. In addition, a progressive decrease in TFPI plasma activity was observed in both the proximal and the distal samples, indicating consumption of TFPI during thrombus formation. In 10 additional rabbits, CFRs were abolished by administration of aspirin (10 mg/kg). In the animals in which aspirin abolished CFRs, endogenous TFPI was depleted by a bolus of a polyclonal antibody against rabbit TFPI, and the effects on restoration of CFRs were monitored. In 5 of 6 animals in which aspirin abolished CFRs, depletion of endogenous TFPI activity caused full restoration of CFRs.
Conclusions—The data of the present study support the involvement of endogenous TFPI in the process of thrombus formation in vivo and its active role in modulating arterial thrombosis.
Key Words: inhibitors • thromboplastin • coagulation • blood flow
This article has been cited by other articles:
 |
|
 |
|
  J. T.B. Crawley and D. A. Lane The Haemostatic Role of Tissue Factor Pathway Inhibitor Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 233 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jayachandran, A. Sanzo, W. G. Owen, and V. M. Miller Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1908 - H1916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.E. Morange, C. Simon, M.C. Alessi, G. Luc, D. Arveiler, J. Ferrieres, P. Amouyel, A. Evans, P. Ducimetiere, I. Juhan-Vague, et al. Endothelial Cell Markers and the Risk of Coronary Heart Disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study Circulation, March 23, 2004; 109(11): 1343 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Golino, A. Ravera, M. Ragni, P. Cirillo, O. Piro, and M. Chiariello Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes Circulation, December 9, 2003; 108(23): 2864 - 2869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D'Andrea, M. Ravera, P. Golino, A. Rosica, M. De Felice, M. Ragni, P. Cirillo, F. Vigorito, N. Corcione, P. Tommasini, et al. Induction of Tissue Factor in the Arterial Wall During Recurrent Thrombus Formation Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1684 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sundaram, Y. Qi, Z. Shriver, D. Liu, G. Zhao, G. Venkataraman, R. Langer, and R. Sasisekharan Rational design of low-molecular weight heparins with improved invivo activity PNAS, January 21, 2003; 100(2): 651 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.T.M. Tang, J. Knott, J. Nanson, J. Hsu, M.P. Haw, and S.K. Ohri A prospective randomized study to evaluate the renoprotective action of beating heart coronary surgery in low risk patients Eur. J. Cardiothorac. Surg., July 1, 2002; 22(1): 118 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kato Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor: Basic and Clinical Aspects Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 539 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Golino, P. Cirillo, P. Calabro', M. Ragni, D. D'Andrea, E. V. Avvedimento, F. Vigorito, N. Corcione, F. Loffredo, and M. Chiariello Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries J. Am. Coll. Cardiol., August 1, 2001; 38(2): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Westrick, P. F. Bodary, Z. Xu, Y.-C. Shen, G. J. Broze, and D. T. Eitzman Deficiency of Tissue Factor Pathway Inhibitor Promotes Atherosclerosis and Thrombosis in Mice Circulation, June 26, 2001; 103(25): 3044 - 3046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Singh, S. Pan, C. S. Mueske, T. Witt, L. S. Kleppe, T. E. Peterson, A. Slobodova, J.-Y. Chang, N. M. Caplice, and R. D. Simari Role for Tissue Factor Pathway in Murine Model of Vascular Remodeling Circ. Res., July 6, 2001; 89(1): 71 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kato Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor: Basic and Clinical Aspects Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 539 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Eitzman, R. J. Westrick, X. Bi, S. L. Manning, J. E. Wilkinson, G. J. Broze, and D. Ginsburg Lethal Perinatal Thrombosis in Mice Resulting From the Interaction of Tissue Factor Pathway Inhibitor Deficiency and Factor V Leiden Circulation, May 7, 2002; 105(18): 2139 - 2142. [Abstract] [Full Text] [PDF]
|
|